Organogenesis Q2 revenue $123.2M (+79%), net income $20.7M; new $200M credit facility

Organogenesis Holdings Inc.

2021-Q2 EPS reported $0.23 revenue$225,748,000

Net revenue $123.2M (+79% YoY); Advanced Wound Care $111.4M (+87%), Surgical & Sports Med $11.8M (+27%).
Net income $20.7M ($0.15 diluted EPS) vs loss $5.2M; adjusted EBITDA $25.1M (20.4% of revenue).
FY2021 revenue guidance raised to $456-472M (35-40% growth); GAAP net income and adjusted EBITDA positive.
New $200M credit facility ($75M term loan + $125M revolver) with LIBOR-based pricing; prior facility terminated.
Legacy stockholders agreed not to sell shares until March 1, 2022 unless via underwritten secondary offering.

item 1.01 item 1.02 item 2.02 item 2.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.